Sector Experts

Andrew Fein

H.C. Wainwright & Co.

Image: Andrew Fein

In May 2013, Andrew Fein joined H.C. Wainwright & Co. as managing director and senior biotechnology analyst to cover companies in the biotechnology and life sciences sectors. He has 13 years of experience in healthcare and biotechnology equity research. He was previously a senior analyst at Chardan Capital Markets and held prior research positions at Jefferies & Co., Piper Jaffrey, Collins Stewart, Leerink Swann LLC and J.P. Morgan.




Recent Interviews

Biotech Investor Realism with Andrew Fein (8/29/13) Expert healthcare company watcher Andrew Fein of H.C. Wainwright & Co. knows how the sausage is made in the stock analyst factory. And he doesn't pull any punches: In this interview with The Life Sciences Report, Fein dishes out praise for sticking to sellside fundamentals and suggests skimming off bloggers who have yet to earn their analytical chops. He rounds out the menu by naming biotech companies with the potential to rise to the top of the simmering biotech market.

Recent Quotes

"THLD presented data from Part C of its Phase 1/2 TH-302 study in MM." (12/8/14) Threshold Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"We like the risk/reward of a long position in NBS." (11/19/14) NeoStem Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"THLD has done a remarkable job." (11/12/14) Threshold Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"The green light for THLD's Phase 3 study of TH-302 is positive." (9/23/14) Threshold Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"We are initiating coverage on THLD with a Buy rating." (9/5/14) Threshold Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"SYN has a worldwide license and option agreement with Cedars-Sinai." (12/10/13) Synthetic Biologics Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"CPRX stands out as the top LEMS therapeutics contender." (10/31/13) Catalyst Pharmaceutical Partners Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"In our view, the odds of commercial success remain still remain in CPRX's favor." (10/18/13) Catalyst Pharmaceutical Partners Inc. - Andrew Fein, H.C. Wainwright & Co. More >

more comments

"We believe CYTR's shares will continue to perform well into 2013 (9/30/13) CytRx Corp. - Andrew Fein, H.C. Wainwright & Co. More >

"We are reiterating our Buy rating on NBS." (9/13/13) NeoStem Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"We are initiating coverage on CPRX with a Buy rating." (8/29/13) Catalyst Pharmaceutical Partners Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"We believe results from the phase 2b study will ignite investor interest in CYTR." (8/29/13) CytRx Corp. - The Life Sciences Report Interview with Andrew Fein More >

"NBS' data readout next year ought to validate its stem cell-based treatment for heart disease." (8/29/13) NeoStem Inc. - The Life Sciences Report Interview with Andrew Fein More >

"Given the wave of consolidation and investor interest in the anti-infective space, SYN could do well." (8/29/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Andrew Fein More >

"CYTR remains on track to report data from a phase 2b study in H2/13." (8/14/13) CytRx Corp. - Andrew Fein, H.C. Wainwright & Co. More >

"We are initiating coverage on RNN." (8/13/13) Rexahn Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"NBS announced a collaboration for development of regulatory T cells." (7/22/13) NeoStem Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"We are initiating coverage on NBS with a Buy rating." (6/27/13) NeoStem Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"We are initiating coverage on SYN with a Buy rating." (6/27/13) Synthetic Biologics Inc. - Andrew Fein, H.C. Wainwright & Co. More >

fewer comments


Due to permission requirements, not all quotes are shown.